Profile data is unavailable for this security.
About the company
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
- Revenue in USD (TTM)3.85m
- Net income in USD-70.09m
- Incorporated2016
- Employees34.00
- LocationIkena Oncology Inc50 Northern Ave.BOSTON 02210United StatesUSA
- Phone+1 (857) 343-8292
- Fax+1 (302) 655-5049
- Websitehttps://www.ikenaoncology.com
More ▼
Mergers & acquisitions
| Acquired company | IKNA:NMQ since announced | Transaction value |
|---|---|---|
| Pionyr Immunotherapeutics Inc | -69.13% | 31.44m |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cognition Therapeutics Inc | 0.00 | -28.77m | 72.91m | 25.00 | -- | 2.52 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 73.15m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| FibroGen Inc | 167.49m | -240.46m | 73.91m | 486.00 | -- | -- | -- | 0.4413 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Verastem Inc | 0.00 | -105.52m | 74.33m | 73.00 | -- | 2.96 | -- | -- | -4.40 | -4.40 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -86.34 | -62.70 | -108.04 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.4703 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Allakos Inc | 0.00 | -214.44m | 74.43m | 131.00 | -- | 0.7094 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 76.04m | 81.00 | -- | 0.7854 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Chimerix Inc | 41.00k | -82.59m | 77.31m | 72.00 | -- | 0.444 | -- | 1,885.51 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| IO Biotech Inc | 0.00 | -88.50m | 77.74m | 68.00 | -- | 0.6733 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 78.49m | 23.00 | -- | -- | -- | 1,154.28 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 78.66m | 34.00 | -- | 0.5064 | -- | 20.44 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -65.10m | 80.77m | 63.00 | -- | 0.3798 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 81.24m | 91.00 | -- | 0.5719 | -- | 2.61 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 81.50m | 18.00 | -- | 2.06 | -- | 11,642.45 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Data as of Jul 03 2024. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD
25.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 4.77m | 9.88% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.65m | 3.43% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.51m | 3.13% |
| Verition Fund Management LLCas of 31 Mar 2024 | 1.13m | 2.35% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 776.60k | 1.61% |
| Geode Capital Management LLCas of 31 Mar 2024 | 597.28k | 1.24% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 513.44k | 1.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 482.65k | 1.00% |
| Acuitas Investments LLCas of 31 Mar 2024 | 397.75k | 0.82% |
| Adage Capital Management LPas of 31 Mar 2024 | 287.90k | 0.60% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
